12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Spiriva HandiHaler tiotropium: Phase IV data

A double-blind, U.S. and Canadian Phase IV trial (205.440) in 126 patients with mild to moderate COPD showed that once-daily 18 µg Spiriva HandiHaler tiopropium significantly improved mean isotime inspiratory capacity, the primary endpoint, from baseline to week 6 during rest (125 mL, p<0.0001) and exercise (65 mL, p=0.009) compared to placebo. Spiriva did not significantly improve the secondary endpoint of exercise duration from baseline to week 6 vs....

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >